ESMO 2023: Low- and High- Volume Disease in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): From CHAARTED to PSMA PET
Current Oncology | Free Full-Text | Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
Imaging of advanced Prostate Cancer
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl2/AS:947382543974400@1602885008617/Key-findings-hormonal-treatment-combined-with-chemotherapy-in-men-presenting-with_Q320.jpg "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial - ScienceDirect
Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
Current usage of stereotactic body radiotherapy for oligometastatic prostate cancer in Korea: patterns of care survey (KROG 19-08) - Bae - Annals of Translational Medicine
Oligometastatic Prostate Cancer – Treatment of the Primary Tumor and Metastasis Directed Therapy
APCCC 2019: Synthesis - Optimal Treatment of Men with Newly Diagnosed Prostate Cancer
Prostate cancer Risk stratification and choice of initial treatment final.pptx
EAU 2019: Conclusions from Recent Oncology Meetings Regarding: Hormone Naïve Prostate Cancer
Rahul Tendulkar, MD on X: "STAMPEDE: adding prostate RT to ADT improved OS for pre-specified subset of low volume mCSPC, but NOT for high volume. https://t.co/PtyKHOScW0 12/21 https://t.co/6XWmUYieDt" / X
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting | Oncology and Therapy
September 15, 2014 - What Constitutes High-Volume/Extensive Disease? - The ASCO Post
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial | PLOS Medicine
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing the definitions of CHAARTED and LATITUDE trial
Current Oncology | Free Full-Text | Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology
Patients' distribution according to LATITUDE and CHAARTED risk criteria... | Download Scientific Diagram
Uncovering the Right Sequence - ppt download
Page 47 - PACE: Advanced Prostate Cancer Consensus
Prostate Cancer News, Reviews & Views: CHAARTED
Thomas E. Keane | Timing of ADT and Chemotherapy
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
